Results 11 to 20 of about 17,227 (165)

Real-Time Positron Emission Tomography Evaluation of Topotecan Brain Kinetics after Ultrasound-Mediated Blood–Brain Barrier Permeability

Pharmaceutics, 2021
Glioblastoma (GBM) is the most common primary adult brain malignancy with an extremely poor prognosis and a median survival of fewer than two years.
Andrei Molotkov, Patrick Carberry, Martin A. Dolan, Simon Joseph, Sidney Idumonyi, Shunichi Oya, John Castrillon, Elisa E. Konofagou, Mikhail Doubrovin, Glenn J. Lesser, Francesca Zanderigo, Akiva Mintz   +11 more
doaj   +1 more source

Elucidation of Mechanisms of Topotecan-Induced Cell Death in Human Breast MCF-7 Cancer Cells by Gene Expression Analysis

Frontiers in Genetics, 2020
Topotecan is a clinically active anticancer agent for the management of various human tumors. While the principal mechanism of tumor cell killing by topotecan is due to its interactions with topoisomerase I and formation of DNA double-strand breaks ...
Birandra K. Sinha, Erik J. Tokar, Pierre R. Bushel   +2 more
doaj   +1 more source

Inhalation delivery dramatically improves the efficacy of topotecan for the treatment of local and distant lung cancer

Drug Delivery, 2021
Topotecan is potent anti-cancer drug approved for various malignancies but hematopoietic toxicities undermine its wider application and use of its most effective dose. This study aims to improve these limitations through inhalation-delivery.
Philip J. Kuehl, Christin M. Yingling, Devon Dubose, Michael Burke, David A. Revelli, Wenshu Chen, Wendy W. Dye, Steven A. Belinsky, Mathewos Tessema   +8 more
doaj   +1 more source

DNA repair and cholesterol-mediated drug efflux induce dose-dependent chemoresistance in nutrient-deprived neuroblastoma cells

iScience, 2021
Summary: Neuroblastoma is a solid, heterogeneous pediatric tumor. Chemotherapy is widely used to treat neuroblastoma. However, dose-dependent responses and chemoresistance mechanisms of neuroblastoma cells to anticancer drugs remain challenging. Here, we
Soo Yeon Chae, Dowoon Nam, Do Young Hyeon, Areum Hong, Timothy Dain Lee, Sujin Kim, Dongjoon Im, Jiwon Hong, Chaewon Kang, Ji Won Lee, Daehee Hwang, Sang-Won Lee, Hugh I. Kim   +12 more
doaj   +1 more source

The Lipophilic Purine Nucleoside—Tdp1 Inhibitor—Enhances DNA Damage Induced by Topotecan In Vitro and Potentiates the Antitumor Effect of Topotecan In Vivo

Molecules, 2022
The use of cancer chemotherapy sensitizers is a promising approach to induce the effect of clinically used anticancer treatments. One of the interesting targets is Tyrosyl-DNA Phosphodiesterase 1 (Tdp1), a DNA-repair enzyme, that may prevent the action ...
Irina A. Chernyshova, Aleksandra L. Zakharenko, Nikolay N. Kurochkin, Nadezhda S. Dyrkheeva, Tatyana E. Kornienko, Nelly A. Popova, Valeriy P. Nikolin, Ekaterina S. Ilina, Timofey D. Zharkov, Maxim S. Kupryushkin, Vladimir E. Oslovsky, Mikhail S. Drenichev, Olga I. Lavrik   +12 more
doaj   +1 more source

Comparison of the second-line treatments for patients with small cell lung cancer sensitive to previous platinum-based chemotherapy: A systematic review and Bayesian network analysis

Frontiers in Oncology, 2023
ObjectiveIt remains unclear what the best second-line treatment is for patients with small-cell lung cancer sensitive to previous platinum-based chemotherapy.MethodsWe systematically screened randomized controlled trials from several online databases ...
Hekai Shi, Nuojin Guo, Zeming Zhao, Ligang Liu, Tianyi Ni, Jinye Zhang, Yingjie Lu   +6 more
doaj   +1 more source

Exploration of the intercellular heterogeneity of topotecan uptake into human breast cancer cells through compartmental modelling [PDF]

, 2008
A mathematical multi-cell model for the in vitro kinetics of the anti-cancer agent topotecan (TPT) following administration into a culture medium containing a population of human breast cancer cells (MCF-7 cell line) is described.
Chappell, M. J. (Michael J.), Godfrey, Keith, Godfrey, K. R., Evans, Neil D., Cheung, S. Y. Amy, Errington, Rachel J., Cheung, S. Y. A., Errington, Rachel Jane, Smith, Paul J., Evans, N. D., Smith, Paul James, Chappell, M. J.   +11 more
core   +1 more source

A phase I and pharmacokinetic study of intraperitoneal topotecan [PDF]

, 2001
Purpose: To evaluate the feasibility and pharmacology of intraperitoneal (IP) topotecan. Patients and methods: Fifteen patients with recurrent ovarian cancer in a phase I trial were treated with escalating IP topotecan doses (5-30 mg/m(2)) for ...
van der Zee, AGJ, Beijnen, JH, A M E Bos, N H Mulder, L S Hofstra, P H B Willemse, Rosing, H, A G J van der Zee, de Vries, EGE; id_orcid, Hofstra, LS, Willemse, PHB, de Vries, EGE, J H Beijnen, J G Aalders, Mulder, NH, Aalders, JG, E G E de Vries, H Rosing   +17 more
core   +8 more sources

A coupled drug kinetics-cell cycle model to analyse the response of human cells to intervention by topotecan [PDF]

, 2008
A model describing the response of the growth of single human cells in the absence and presence of the anti-cancer agent topotecan (TPT) is presented. The model includes a novel coupling of both the kinetics of TPT and cell cycle responses to the agent ...
Ali, Reza, Khan, Imtiaz Ali, Godfrey, Keith, Evans, Neil D., Khan, I. A., Errington, Rachel J., Campbell, L., Smith, Paul J., Smith, Paul James, Ali, R., Chappell, M. J. (Michael J.), Chappell, Michael J., Godfrey, K. R., Campbell, Lee, Errington, Rachel Jane, Evans, N. D.   +15 more
core   +1 more source

OUR EXPERIENCE WITH TOPOTECAN AS SECOND- LINE TREATMENT OF PATIENTS WITH RELAPSED SMALL CELL LUNG CANCER [PDF]

Journal of IMAB, 2010
Objectives: Single agent intravenous Topotecan is an effective treatment for small cell lung cancer /SCLC/ after failure of first- line chemotherapy. The aim of this study was to evaluate the efficacy and toxicity of intravenous Topotecan in recurrent ...
Deyan Davidov
doaj   +1 more source